Ken Griffin Xeris Biopharma Holdings, Inc. Transaction History
Citadel Advisors LLC
- $505 Billion
- Q3 2024
A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Xeris Biopharma Holdings, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 96,500 shares of XERS stock, worth $279,850. This represents 0.0% of its overall portfolio holdings.
Number of Shares
96,500
Previous 88,500
9.04%
Holding current value
$279,850
Previous $199,000
38.19%
% of portfolio
0.0%
Previous 0.0%
Shares
5 transactions
Others Institutions Holding XERS
# of Institutions
141Shares Held
59.9MCall Options Held
148KPut Options Held
45.7K-
Black Rock Inc. New York, NY10.3MShares$30 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA7.77MShares$22.5 Million0.0% of portfolio
-
Caxton Corp Princeton, NJ5.11MShares$14.8 Million62.59% of portfolio
-
Center Book Partners LP Greenwich, CT3.48MShares$10.1 Million0.64% of portfolio
-
Geode Capital Management, LLC Boston, MA3.33MShares$9.67 Million0.0% of portfolio
About Xeris Biopharma Holdings, Inc.
- Ticker XERS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 135,956,992
- Market Cap $394M
- Description
- Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies for patient populations in endocrinology, neurology, and gastroenterology. The company markets Gvoke, a ready-to-use liquid glucagon for the treatment of severe hypoglycemia; and Keveyis, a therapy for the treatment of hyperkalemic, h...